dren over 1 year of age with stage-3 or stage-4 neuroblastoma (Hsiao et al. 1990). Its value as a measure of the degree of neuroendocrine differentiation has not yet been thoroughly investigated.

Neuropeptide Y is a 36 amino acid peptide which is co-localized with catecholamines and may act as neuromodulator of cardiovascular and neuroendocrine function, e.g., of noradrenalin release and enhancing its effect. High serum levels were detected in neuroblastomas and pheochromocytomas depending on stage (higher in disseminated disease) and differentiation (lower in differentiated tumors; Kogner et al. 1993). The additional clinical use of neu-ropeptide-Y determination in patients with neuro-blastoma remains to be established.

0 0

Post a comment